Tesofensine

Also known as Tesofensine free base, NS-2330, NS2330, NS 2330

Research Goal: Analyzing the suppression of appetite and increase in resting energy expenditure through the modulation of neurotransmitter reuptake in the hypothalamus.

Route

Oral

Dose range

250 mcg – 1 mg

Frequency

Once per day

Cycle length

12–24 weeks

Not currently stocked by N1 Aminos. Browse what is in stock →

Overview

Research Goal: Analyzing the suppression of appetite and increase in resting energy expenditure through the modulation of neurotransmitter reuptake in the hypothalamus.

Preparation: Typically administered as an oral capsule or tablet. No reconstitution or injection required.

Studied benefits

  • A potent triple monoamine reuptake inhibitor (acting on dopamine, serotonin, and noradrenaline)
  • While not a peptide, it is widely researched for its significant weight loss effects, driven by intense appetite suppression and an increase in resting energy expenditure

Reported side effects

  • Common side effects include dry mouth, insomnia, increased heart rate, and potential elevations in blood pressure
  • It may also lead to gastrointestinal discomfort or transient mood changes

Protocol

Dosing Schedule (Oral)

Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.

PhaseDaily Dose (mg)FocusLog
Initial Phase0.25 mgTolerance Assessment+ Log
Standard Research0.50 mgAppetite Suppression+ Log
Advanced Study1.0 mgMaximum Metabolic Impact+ Log

Frequency

Once per day.

Timing

Morning administration to prevent potential insomnia side effects.

Cycle length

12–24 weeks.

Context

Lifestyle considerations

Maintain a high-protein, balanced diet to safeguard lean muscle mass while this triple monoamine reuptake inhibitor works to significantly suppress appetite and increase resting energy expenditure. Incorporate regular physical activity to support cardiovascular health and manage potential shifts in heart rate or blood pressure, which are common with norepinephrine-active compounds. Ensure 7–9 hours of quality sleep to support neural recovery and mood stabilization. Maintain optimal hydration and monitor for dry mouth or sleep disturbances, adjusting the timing of administration to early morning to minimize interference with the body’s circadian rhythm.

Evidence

Research summaries

Effect of tesofensine on bodyweight loss, body composition, and safety in obese patients

Findings: Drives 9.2-10.6% total weight loss (0.5-1.0 mg doses) versus 2% placebo over 24 weeks on calorie restriction, with 6.7 kg fat loss and cardiometabolic gains.

Across 203 obese adults (BMI 30-40 kg/m²), tesofensine scaled weight reductions dose-dependently, halving fat mass while safeguarding muscle, shrinking waists, and optimizing triglycerides/insulin. Heart rate rose modestly without dropout spikes (21% overall), evidencing a potency-safety profile eclipsing approved agents and validating central monoamine modulation for sustained obesity intervention.

Read the study ↗

Weight loss produced by tesofensine in patients with obesity

Findings: Nets ~4% placebo-subtracted loss in 14 weeks sans lifestyle changes, mirroring sibutramine efficacy minus hypertension risks.

Early human data pinpointed appetite suppression as the core driver, with metabolic uplifts suggesting repurposing potential from Parkinson's origins—laying groundwork for tesofensine's obesity pivot through balanced neurotransmitter enhancement.

Read the study ↗

Tesofensine induces appetite suppression and weight loss with superior effects in obese rats

Findings: Excels in diet-induced obesity via hypothalamic GABA silencing, blocks post-serotonergic rebound, no palatability disruption.

Rodent studies revealed amplified anorexigenic potency in obese states (higher metabolic ratio), with lateral hypothalamus targeting explaining human translations—serotonergic combos extended effects, forecasting hybrid therapies for weight maintenance.

Read the study ↗

Tesofensine, a novel antiobesity drug, silences GABAergic neurons in the Lateral Hypothalamus

Findings: Suppresses feeding-promoting GABA cells, augments GLP-1 loss, low stereotypy versus stimulants.

Optogenetic validation confirmed neuronal specificity, boosting obese outcomes without aversion—minimal abuse signals enhance its profile for combo regimens targeting intractable obesity circuits. Tesofensine's hypothalamic precision unleashes 9-11% losses via appetite-energy synergy, trumping peers in obese models with rebound-proof potential, despite stalled approval.

Read the study ↗
More references (4)

Identification

Chemistry

common names
Tesofensine, Tesofensine free base, NS-2330, NS2330, NS 2330, CL-201, Tesofensin, Tesufensin
cas
195875-84-4 (free base)
molecular weight
328.28 Da (free base); approximately 520.40 Da (citrate salt form)
source
Synthetic; not naturally occurring in biological systems
biosynthesis
Nonribosomal small-molecule synthesis via organic chemistry methodologies

Keep exploring

Related peptides

Educational use only. The protocols shown summarise published research and community practice for informational purposes. They are not medical advice, not a prescription, and not a recommendation to use any compound. Research peptides are generally not approved for human use. Consult a licensed clinician. Full disclaimer.
Ask the advisor